Notes
The study was funded by LEO Pharma Oy, Finland.
Reference
Soini EJ, et al. Cost-Utility of First-Line Actinic Keratosis Treatments in Finland. Advances in Therapy : 26 May 2015. Available from: URL: http://doi.org/10.1007/s12325-015-0211-7
Rights and permissions
About this article
Cite this article
Ingenol mebutate for AK: better outcomes at acceptable cost. PharmacoEcon Outcomes News 729, 18 (2015). https://doi.org/10.1007/s40274-015-2175-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-015-2175-x